Guardant Health (GH) Stock Price, News & Analysis

Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: $30.83 to $33.45
• 50-Day Range: $20.20 to $31.61
• 52-Week Range: $15.81 to $37.04
• Volume: 2.17 million shs
• Average Volume: 2.07 million shs
• Market Capitalization: $4.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.60
• Consensus Rating: Moderate Buy

Guardant Health Stock Analysis - MarketRank™

Guardant Health scored higher than 80% of companies evaluated by MarketBeat, and ranked 244th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Guardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Guardant Health has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Guardant Health are expected to grow in the coming year, from ($3.38) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Guardant Health is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guardant Health is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.30% of the outstanding shares of Guardant Health have been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Guardant Health has recently decreased by 25.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardant Health does not currently pay a dividend.

Dividend Growth

Guardant Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.51

Percentage of Shares Shorted

8.30% of the outstanding shares of Guardant Health have been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Guardant Health has recently decreased by 25.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.66

News Sentiment

Guardant Health has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Guardant Health this week, compared to 6 articles on an average week.

Search Interest

13 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,590.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Guardant Health is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GH Stock Analysis - Frequently Asked Questions

How have GH shares performed this year?

Guardant Health's stock was trading at $27.05 on January 1st, 2024. Since then, GH shares have increased by 20.7% and is now trading at $32.65.
View the best growth stocks for 2024 here.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.33. Guardant Health's revenue for the quarter was up 33.9% compared to the same quarter last year.

When did Guardant Health IPO?

Guardant Health (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Who are Guardant Health's major shareholders?

Guardant Health's top institutional investors include Wellington Management Group LLP (8.20%), Baillie Gifford & Co. (4.77%), Eventide Asset Management LLC (3.11%) and Geode Capital Management LLC (2.28%). Insiders that own company stock include Helmy Eltoukhy, Amirali Talasaz, Amelia Merrill, Kumud Kalia, Meghan V Joyce and Stanley J Meresman.
View institutional ownership trends.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Salesforce (CRM), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:GH
• CUSIP: N/A
• CIK: 1576280
• Web: www.guardanthealth.com
• Phone: (855) 698-8887
• Fax: 888-974-4258
• Employees: 1,779
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.60
• High Stock Price Target: $50.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: +24.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-479,450,000.00
• Net Margins: -74.02%
• Pretax Margin: -74.02%
• Return on Equity: -1,200.44%
• Return on Assets: -29.88%

Debt

• Debt-to-Equity Ratio: 16.70
• Current Ratio: 6.22
• Quick Ratio: 5.85

Sales & Book Value

• Annual Sales: $692.26 million
• Price / Sales: 5.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.49) per share
• Price / Book: -66.63

Miscellaneous

• Outstanding Shares: 123,555,000
• Free Float: 116,759,000
• Market Cap: $4.03 billion
• Optionable: Not Optionable
• Beta: 1.11